{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"52.5","value":"79.8"},{"groupId":"OG001","spread":"46.0","value":"80.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"382"},{"groupId":"OG001","value":"297"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"47.2","value":"122"},{"groupId":"OG001","spread":"66.0","value":"129"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"365"},{"groupId":"OG001","value":"245"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"70.4","value":"153"},{"groupId":"OG001","spread":"63.4","value":"157"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"321"},{"groupId":"OG001","value":"183"}],"units":"Participants"}],"title":"Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"96.8","value":"216"},{"groupId":"OG001","spread":"79.8","value":"193"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"104"}],"units":"Participants"}],"title":"Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"103","value":"235"},{"groupId":"OG001","spread":"79.8","value":"220"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"title":"Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"75.7","value":"244"},{"groupId":"OG001","spread":"92.5","value":"233"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"title":"Cycle 24 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"97.2","value":"259"},{"groupId":"OG001","spread":"60.5","value":"258"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Cycle 32 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"36.9","value":"18.8"},{"groupId":"OG001","spread":"12.7","value":"9.53"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"64"}],"units":"Participants"}],"title":"Day 120 Post Dose of Last Blinded Atezo Trt"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"102","value":"154"},{"groupId":"OG001","spread":"83.8","value":"124"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"148"}],"units":"Participants"}],"title":"Study Drug Early Discontinuation"}],"denoms":[{"counts":[{"groupId":"OG000","value":"382"},{"groupId":"OG001","value":"297"}],"units":"Participants"}],"description":"Minimum atezolizumab serum concentration.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received blinded atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).","id":"OG000","title":"Atezolizumab+Gemcitabine+Carboplatin/Cisplatin"},{"description":"Eligible participants received open-label atezolizumab as monotherapy.","id":"OG001","title":"Atezolizumab Monotherapy"}],"paramType":"MEAN","populationDescription":"The pharmacokinetic (PK)-evaluable population is defined as all participants dosed with atezolizumab who have at least one post-baseline PK result.","reportingStatus":"POSTED","timeFrame":"Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 8 Day 1, Cycle 16 Day 1, Cycle 24 Day 1, Cycle 32 Day 1, Day 120 post dose of last blinded atezolizumab treatment, and study drug early discontinuation","title":"Minimum Atezolizumab Serum Concentration","type":"SECONDARY","unitOfMeasure":"μg/ mL"}